Lumos Pharma — NewLink Genetics — FY2015 Earnings Presentation
10 slides from Lumos Pharma's earnings presentation, Feb 29, 2016
Slide 1: Fourth Quarter and Year-End 2015 Operational and Financial Results
Fourth Quarter and Year-End 2015 Operational and Financial Results Nasdaq: NLNK February 29, 2016
Slide 2: Agenda
Agenda 2 Introduction Mr. Jack Henneman, Executive Vice President & CFO Key 2015 Takeaways & 2016 Priorities Dr. Charles J. Link, Chairman, CEO & CSO Highlights of 2015 - 2016 Clinical Programs Dr. Nicholas N. Vahanian, President & CMO Fourth Quarter and Year-End 2015 Financial Results Mr. J
Slide 3: Safe Harbor Statement
Safe Harbor Statement These slides contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve substantial risks and uncertainties and actual results may differ from expectations, estimates and projections and cons
Slide 4: NewLink Genetics Programs
4 NewLink Genetics Programs HyperAcute® Cellular Immunotherapies Pancreatic NSCLC Advanced Melanoma Prostate Kidney IDO Pathway Inhibitors Breast Prostate Pancreatic Advanced Melanoma Refractory Malignant Brain Tumors Solid Tumors Infectious Diseases Ebola vaccine program Zika
Slide 5: Key 2015 Takeaways
Key 2015 Takeaways Exceptional Year with Strong Clinical & Pre-Commercial Advancements IMPRESS trial advancing according to plan Increased manufacturing and pre-commercialization efforts for algenpantucel-L Made clinical progress in Phase 1 and Phase 2 trials for additional HyperAcute® Cellula
Slide 6: 2016 Business Priorities
2016 Business Priorities 6 Charles J. Link, Jr., Chairman, CEO, & CSO HyperAcute® Cellular Immunotherapy IMPRESS Phase 3 – Report on top-line results – Execute on regulatory strategy with FDA – Continue U.S. commercialization planning – Explore partnering strategy outside U.S. HyperAcute® Cellul
Slide 7: Highlights of 2015 Clinical Programs
Highlights of 2015 Clinical Programs 7 Nicholas Vahanian, M.D., President & Chief Medical Officer HyperAcute® Cellular Immunotherapy HyperAcute® Cellular Immunotherapies continued to move forward with clinical programs in pancreatic, NSCLC, melanoma and kidney cancers Completed enrollment of PIL
Slide 8: Anticipated Highlights for 2016 Clinical Programs
Anticipated Highlights for 2016 Clinical Programs 8 Nicholas Vahanian, M.D., President & Chief Medical Officer HyperAcute® Cellular Immunotherapies Top-line results from the pivotal Phase 3 IMPRESS study Update on the timing of results for the PILLAR study Recently began enrollment in triple c
Slide 9: Fourth Quarter and Year-End 2015 Financial Results
Fourth Quarter and Year-End 2015 Financial Results 9 Jack Henneman, EVP and Chief Financial Officer Strong Capital Position Stable and reliable cash position - $197.8M at YE 2015 / $202.8M at YE 2014 Goal and expectation to finish 2016 with two years of cash-on-hand Multiple Value Drivers Increa
Slide 10: Q&A
Brewin Q&A